van der Vliet, Daan https://orcid.org/0000-0001-7317-9679
Di, Xinyu
Shamorkina, Tatiana M. https://orcid.org/0000-0002-4191-6061
Coulon-Bainier, Claire
Pavlovic, Anto
van der Vliet, Iris A. C. M.
Zeng, Yingyu https://orcid.org/0009-0008-8273-9699
Macnair, Will https://orcid.org/0000-0001-6357-0834
van Egmond, Noƫlle
Chen, J. Q. Alida
van den Bosch, Aletta M. R. https://orcid.org/0000-0001-8886-8928
Engelenburg, Hendrik J.
Wever, Dennis https://orcid.org/0000-0002-0801-4453
Mason, Matthew R. J.
Driever, Wouter P. F. https://orcid.org/0000-0002-9250-0381
Gagestein, Berend
Dusseldorp, Elise
van Eijk, Marco
Grether, Uwe https://orcid.org/0000-0002-3164-9270
,
van den Bosch, Aletta M. R.
de Goeij, Mignon
Rozemuller, Annemieke J. M.
Harms, Amy C. https://orcid.org/0000-0002-2931-4295
Hankemeier, Thomas https://orcid.org/0000-0001-7871-2073
Collin, Ludovic
Heck, Albert J. R. https://orcid.org/0000-0002-2405-4404
Huitinga, Inge https://orcid.org/0000-0002-4878-8920
van der Stelt, Mario https://orcid.org/0000-0002-1029-5717
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184.034.019)
NWO Zwaartekracht program
Stichting MS Research
Article History
Received: 6 November 2024
Accepted: 15 April 2026
First Online: 21 May 2026
Competing interests
: C.C.-B., A.P., W.M., U.G. and L.C. are employees of F. Hoffmann-La Roche, which holds patents on inhibitors of MAGL. M.v.d.S. is an author on patents describing inhibitors of MAGL. The other authors declare no competing interests.